Bostongene announces partnership with takeda to evaluate immunotherapies using ai-powered molecular profiling

Waltham, mass.--(business wire)--bostongene, a leading provider of artificial intelligence (ai)-driven molecular and immune profiling solutions, announced that it will collaborate with takeda on immuno-oncology focused research studies. this partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes. takeda will leverage bostongene's ai-powered multiomic.
TAK Ratings Summary
TAK Quant Ranking